Literature DB >> 25441136

Pulmonary resection after pneumonectomy.

Olaf Mercier1, Marc de Perrot1, Shaf Keshavjee2.   

Abstract

Limited lung resection for second primary lung cancer after pneumonectomy is a worthwhile procedure in appropriately selected patients because it carries a low operative risk and allows for longterm survival with good quality of life. Operations for metachronous cancers had a survival benefit that approximated the expected survival for primary lung cancer. The prognosis is poor for patients with N2 status and for those treated by second surgery earlier than 2 years after the first procedure. Careful selection of potential candidates for remaining lung surgery with special attention to functional cardiopulmonary reserve and lung cancer extension is mandatory for optimal early postoperative results and a long-term beneficial effect. Wedge resection with negative margins is the preferred procedure for peripheral tumors. Central tumors would benefit more from segmentectomy. With the exception of middle lobectomy, lobectomy should be avoided because of its negative impact on cardiopulmonary reserve and outcomes. In highly selected patients, surgical resection of a second primary NSCLC after pneumonectomy following these principles may achieve a 5-year survival rate of up to 63%. SBRT has shown promising early results as an alternative to surgical resection in inoperable patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lung cancer; Pneumonectomy; Recurrence; Surgery; Wedge resection

Mesh:

Year:  2014        PMID: 25441136     DOI: 10.1016/j.thorsurg.2014.07.008

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  1 in total

1.  Thoracoscopic partial lung resection following pneumonectomy: a report of three cases.

Authors:  Hidenori Goto; Mingyon Mun; Shohei Mori; Joji Samejima; Yosuke Matsuura; Masayuki Nakao; Hirohumi Uehara; Ken Nakagawa; Sakae Okumura
Journal:  J Cardiothorac Surg       Date:  2019-11-04       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.